Alexion Pharmaceuticals Inc., of New Haven, Conn., reported first-quarter revenues of $1.14 billion, a 23% year-over-year increase, as compared to consensus estimates of about $1.1 billion, with non-GAAP earnings per share of $2.39, a 42% year-over-year increase, vs. estimates of $2.20.